Nicotinamide adenine dinucleotide (NAD+) has emerged as one of the most intensively studied molecules in contemporary metabolic and aging research. As an obligate coenzyme in hundreds of enzymatic reactions and a critical substrate for non-redox signaling enzymes, NAD+ occupies a uniquely central position in cellular biology. The well-documented decline of NAD+ levels with advancing age across multiple tissue types and species has positioned this dinucleotide at the intersection of metabolism, genomic maintenance, and longevity biology. This article reviews the current literature on NAD+ biochemistry, its major consuming enzymes, and the biosynthetic pathways that govern its availability.
Structural Overview
Nicotinamide adenine dinucleotide is a dinucleotide composed of two nucleotides joined through their phosphate groups: one containing an adenine nucleobase and the other containing nicotinamide. With a molecular weight of approximately 663 Da, NAD+ exists in two interconvertible forms — the oxidized form (NAD+) and the reduced form (NADH) — which together constitute one of the most fundamental redox couples in biochemistry. The molecule was first identified by Arthur Harden and William John Young in 1906 during investigations of yeast fermentation, and its complete structure was elucidated by Hans von Euler-Chelpin in the subsequent decades.
NAD+ participates in over 500 enzymatic reactions across all domains of life, making it one of the most versatile coenzymes in biology. Its functions extend well beyond electron transfer in metabolic pathways; NAD+ serves as a consumed substrate for several families of signaling enzymes, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthases. This dual role as both a recyclable redox cofactor and a consumed signaling substrate creates a complex metabolic economy in which multiple enzymatic systems compete for a shared and finite NAD+ pool.
Age-related decline in tissue NAD+ concentrations has been documented across mammalian species and tissue types, with studies in murine models demonstrating reductions of 30–50% in hepatic, muscular, and neural tissues by mid-to-late life compared to young adult baselines. Investigations in human cohorts have corroborated these findings, with declining NAD+ levels observed in skin, blood, and cerebrospinal fluid with advancing age. This progressive depletion has been attributed to multiple converging factors, including increased consumption by NAD+-degrading enzymes, reduced biosynthetic capacity, and chronic low-grade inflammatory signaling characteristic of the aging phenotype.
Redox Chemistry and Cellular Energetics
The redox function of NAD+ constitutes its most ancient and quantitatively dominant role in cellular metabolism. As the primary electron carrier in catabolic pathways, NAD+ accepts hydride ions (H−) from metabolic substrates, becoming reduced to NADH in the process. This transfer occurs in three major metabolic contexts: glycolysis in the cytoplasm, the tricarboxylic acid (TCA) cycle in the mitochondrial matrix, and beta-oxidation of fatty acids. Each of these pathways generates NADH, which must be reoxidized to NAD+ to sustain continued metabolic flux — a requirement that fundamentally links cellular redox balance to bioenergetic capacity.
The NADH/NAD+ ratio functions as a critical metabolic sensor that influences numerous regulatory nodes within the cell. Elevated NADH/NAD+ ratios, indicative of a highly reduced metabolic state, allosterically inhibit key TCA cycle enzymes including isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase, effectively providing negative feedback on mitochondrial substrate oxidation. Conversely, a low NADH/NAD+ ratio signals metabolic demand and promotes catabolic flux. This ratio-dependent regulation extends to gluconeogenic and lipogenic pathways, establishing the NAD+ redox state as a master integrator of cellular metabolic status.
In oxidative phosphorylation, NADH delivers its electrons to Complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial electron transport chain, the largest protein complex in the inner mitochondrial membrane. Complex I catalyzes the transfer of two electrons from NADH to ubiquinone while translocating four protons across the inner membrane, contributing directly to the electrochemical gradient that drives ATP synthesis by Complex V (ATP synthase). The efficiency of this process is remarkable: the complete oxidation of one molecule of glucose through glycolysis, the TCA cycle, and oxidative phosphorylation yields approximately 30–32 molecules of ATP, with NADH-linked electron transfer accounting for the majority of this yield.
Disruptions to NAD+ availability therefore have cascading consequences for cellular energetics. When NAD+ levels decline, the capacity for substrate oxidation in the TCA cycle diminishes, NADH delivery to the electron transport chain is reduced, and ATP production falls. Cells may compensate by shifting toward glycolytic metabolism, which generates NAD+ through lactate dehydrogenase-mediated conversion of pyruvate to lactate. However, this metabolic shift — reminiscent of the Warburg effect observed in rapidly proliferating cells — is energetically inefficient and unsustainable as a long-term bioenergetic strategy. The metabolic consequences of age-related NAD+ depletion are thus thought to contribute to the progressive decline in mitochondrial function observed across aging tissues.
Sirtuin Biology
The sirtuin family of NAD+-dependent protein deacetylases and ADP-ribosyltransferases represents one of the most significant non-redox functions of NAD+ in cellular biology. Mammals express seven sirtuin isoforms (SIRT1–SIRT7), each with distinct subcellular localizations, substrate specificities, and biological functions. Unlike classical histone deacetylases that simply remove acetyl groups from lysine residues, sirtuins couple deacetylation to NAD+ hydrolysis, consuming one molecule of NAD+ per catalytic event and generating nicotinamide and O-acetyl-ADP-ribose as byproducts. This stoichiometric NAD+ requirement renders sirtuin activity exquisitely sensitive to cellular NAD+ concentrations.
SIRT1, the most extensively studied mammalian sirtuin, is a nuclear and cytoplasmic enzyme whose substrates include the transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). Deacetylation of PGC-1α by SIRT1 activates this master regulator of mitochondrial biogenesis, driving expression of genes encoding mitochondrial transcription factors, electron transport chain components, and fatty acid oxidation enzymes. This SIRT1-PGC-1α axis has been demonstrated to enhance mitochondrial content and oxidative capacity in skeletal muscle, hepatic, and adipose tissue models, establishing a direct mechanistic link between NAD+ availability and mitochondrial function.
SIRT3, the primary mitochondrial deacetylase, resides in the mitochondrial matrix where it deacetylates and regulates the activity of enzymes spanning virtually every major mitochondrial metabolic pathway. Known SIRT3 substrates include acetyl-CoA synthetase 2, long-chain acyl-CoA dehydrogenase, and multiple TCA cycle and electron transport chain components. SIRT3 also deacetylates and activates mitochondrial superoxide dismutase (SOD2/MnSOD), directly linking NAD+-dependent sirtuin activity to mitochondrial antioxidant defense. Studies in SIRT3-knockout murine models have demonstrated hyperacetylation of mitochondrial proteins, impaired fatty acid oxidation, and accelerated age-related metabolic decline.
SIRT6, a chromatin-associated sirtuin with both deacetylase and mono-ADP-ribosyltransferase activities, has emerged as a critical guardian of genomic stability. SIRT6 deacetylates histone H3 at lysines 9 and 56 (H3K9ac and H3K56ac), promoting chromatin compaction at telomeric and pericentromeric regions. SIRT6 also participates directly in DNA double-strand break repair by mono-ADP-ribosylating PARP1, stimulating its recruitment to damage sites. Remarkably, male mice overexpressing SIRT6 exhibit significant lifespan extension, while SIRT6 deficiency results in a progeroid phenotype with genomic instability, metabolic defects, and premature death — underscoring the importance of this NAD+-dependent enzyme in maintaining genomic and organismal integrity.
PARP and DNA Repair
The poly(ADP-ribose) polymerase (PARP) family comprises 17 members in mammals, of which PARP1 is by far the most abundant and catalytically active. PARP1 functions as a DNA damage sensor, binding to single-strand and double-strand breaks through its zinc finger domains and catalyzing the transfer of ADP-ribose units from NAD+ onto acceptor proteins, including histones and PARP1 itself. This process, termed poly(ADP-ribosyl)ation or PARylation, generates branched chains of ADP-ribose that serve as scaffolding for recruitment of DNA repair machinery, chromatin remodeling complexes, and base excision repair factors.
PARP1 is the single largest consumer of NAD+ in the nucleus, and its activity increases dramatically in response to genotoxic stress. Under conditions of extensive DNA damage, PARP1 hyperactivation can deplete the nuclear and cytoplasmic NAD+ pool within minutes, a phenomenon that has been linked to bioenergetic collapse and cell death in models of ischemia-reperfusion injury, neurodegeneration, and inflammatory tissue damage. The concept of a "PARP-sirtuin axis" has emerged from the recognition that PARP1 and sirtuins draw from the same finite NAD+ reservoir; excessive PARP1 activation therefore suppresses sirtuin activity by substrate competition, potentially creating a vicious feedback loop in which DNA damage drives NAD+ depletion, sirtuin inhibition, mitochondrial dysfunction, and further oxidative DNA damage.
Quantitative analyses of NAD+ flux have demonstrated that PARP-mediated consumption accounts for a substantial and increasing fraction of total NAD+ turnover with advancing age. As accumulated DNA damage from endogenous and exogenous sources progressively activates PARP1 in aging tissues, the chronic NAD+ drain redirects an ever-larger share of the available pool away from sirtuin-mediated protective functions. This competitive dynamic has been proposed as a unifying mechanism linking genomic instability, metabolic decline, and mitochondrial dysfunction in the aging phenotype.
The therapeutic implications of PARP-mediated NAD+ consumption have been explored in preclinical models using PARP inhibitors. Genetic deletion or pharmacological inhibition of PARP1 in murine models has been associated with elevated NAD+ levels, increased SIRT1 activity, enhanced mitochondrial function, and protection against metabolic decline in aging and high-fat-diet contexts. However, PARP1 inhibition also compromises DNA repair capacity, introducing a potential tradeoff between NAD+ preservation and genomic maintenance that remains an important consideration in the research landscape.
CD38 and NAD+ Catabolism
CD38 is a multifunctional transmembrane glycoprotein that functions as the dominant NADase in mammalian tissues. Originally identified as a lymphocyte surface antigen, CD38 possesses both NAD+ glycohydrolase and ADP-ribosyl cyclase activities, catalyzing the degradation of NAD+ to nicotinamide and ADP-ribose (or cyclic ADP-ribose). Despite its characterization as an ectoenzyme with its catalytic domain oriented toward the extracellular space, CD38 has been detected in intracellular compartments including the endoplasmic reticulum and mitochondria, where it can directly access and degrade intracellular NAD+ pools.
The role of CD38 in age-related NAD+ decline has been established through a series of landmark studies. CD38 expression increases markedly in multiple tissues with advancing age in murine models, driven in part by inflammatory signaling from senescent cells and infiltrating immune populations. Genetic deletion of CD38 in mice confers dramatic protection against age-related NAD+ depletion, with CD38-knockout animals maintaining youthful NAD+ concentrations, robust sirtuin and PARP activities, and preserved mitochondrial function well into old age. Conversely, forced CD38 overexpression recapitulates the metabolic phenotype of aging, including NAD+ depletion, sirtuin inhibition, and mitochondrial dysfunction.
The connection between CD38, inflammation, and the senescence-associated secretory phenotype (SASP) represents a critical mechanistic link in the biology of NAD+ decline. Senescent cells, which accumulate in tissues with age, secrete a complex mixture of proinflammatory cytokines, chemokines, and proteases that collectively constitute the SASP. Among these factors, several — including IL-6, TNF-α, and lipopolysaccharide-mediated signaling — have been shown to upregulate CD38 expression on resident tissue macrophages and endothelial cells. This creates a paracrine amplification loop in which senescent cell accumulation drives CD38 upregulation, accelerating NAD+ degradation in the surrounding tissue microenvironment.
Pharmacological targeting of CD38 has been explored as a strategy for preserving tissue NAD+ levels. Flavonoid compounds such as apigenin and quercetin have demonstrated CD38 inhibitory activity in preclinical models, and specific small-molecule CD38 inhibitors (including 78c and related thiazoloquin(az)olin(on)es) have shown efficacy in restoring NAD+ levels and metabolic function in aged murine tissues. These findings have further solidified the position of CD38 as the quantitatively most important driver of age-related NAD+ catabolism and a compelling target for research into metabolic aging.
Biosynthesis Pathways
NAD+ biosynthesis in mammalian cells proceeds through three distinct pathways: the de novo synthesis pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide. The relative contribution of each pathway varies by tissue type, metabolic state, and precursor availability, but the salvage pathway is quantitatively dominant in most mammalian tissues, recycling the nicotinamide generated by NAD+-consuming enzymes (sirtuins, PARPs, and CD38) back into NAD+.
The de novo pathway converts the essential amino acid tryptophan to NAD+ through a multi-step enzymatic cascade involving indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) as the initial rate-limiting step, followed by a series of reactions through the kynurenine pathway that ultimately yield quinolinic acid. Quinolinate phosphoribosyltransferase (QPRT) then converts quinolinic acid to nicotinic acid mononucleotide, which enters the shared final steps of NAD+ synthesis. This pathway is most active in hepatic and renal tissues and contributes significantly to whole-organism NAD+ homeostasis, though its flux is relatively low compared to the salvage pathway in most cell types.
The Preiss-Handler pathway utilizes nicotinic acid (vitamin B3, niacin) as its starting substrate. Nicotinic acid phosphoribosyltransferase (NAPRT) catalyzes the conversion of nicotinic acid to nicotinic acid mononucleotide (NaMN), which is then adenylylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to yield nicotinic acid adenine dinucleotide (NaAD+). A final amidation by NAD+ synthetase (NADSYN1) converts NaAD+ to NAD+. This pathway represents the classical vitamin B3 utilization route and is particularly relevant in tissues expressing high levels of NAPRT.
The salvage pathway, the predominant route of NAD+ biosynthesis in most tissues, begins with the conversion of nicotinamide to nicotinamide mononucleotide (NMN) by the enzyme nicotinamide phosphoribosyltransferase (NAMPT). NAMPT catalyzes the rate-limiting step of the salvage pathway and is subject to complex transcriptional and post-translational regulation, including circadian oscillation driven by the CLOCK:BMAL1 transcription factor complex. NMN is subsequently adenylylated by NMNATs (of which three isoforms with distinct subcellular localizations exist) to regenerate NAD+. The importance of NAMPT as the gatekeeper of salvage pathway flux has made it a focus of intense research interest; NAMPT expression and activity decline with age in multiple tissues, and this decline has been implicated as a primary contributor to the progressive erosion of NAD+ levels observed in the aging phenotype. Studies in murine models have demonstrated that interventions enhancing NAMPT expression or providing NAD+ precursors that bypass the NAMPT reaction can restore tissue NAD+ concentrations and ameliorate age-associated metabolic dysfunction in preclinical settings.
Current Research Landscape
The NAD+ research field has expanded rapidly over the past decade, driven by the convergence of metabolomics, genetics, and aging biology. Large-scale studies characterizing tissue-specific NAD+ metabolomes using mass spectrometry-based approaches have provided unprecedented resolution of NAD+ pool sizes, flux rates, and compartmentalization across cell types and physiological states. These quantitative datasets are refining the understanding of how NAD+ is distributed between competing enzymatic consumers and how this distribution shifts with age, metabolic stress, and inflammatory burden.
Preclinical investigations using NAD+ precursors — including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinic acid — have generated a substantial body of data in rodent models. These studies have reported associations between NAD+ repletion and improvements in mitochondrial function, insulin sensitivity, neuronal survival, vascular endothelial function, and stem cell regenerative capacity. The translation of these findings into controlled studies in other model systems remains an active area of investigation, with several groups conducting structured preclinical evaluations to assess reproducibility and define the boundaries of NAD+ precursor efficacy across genetic backgrounds and environmental contexts.
Emerging research frontiers include the spatial biology of NAD+ — understanding how nuclear, cytoplasmic, and mitochondrial NAD+ pools are independently regulated and how inter-compartmental transport mechanisms (including the recently characterized mitochondrial NAD+ transporter SLC25A51) govern local NAD+ availability. Single-cell metabolomics approaches are beginning to reveal cell-to-cell heterogeneity in NAD+ levels within tissues, a dimension that bulk tissue analyses have previously obscured. Additionally, the intersection of NAD+ biology with immunometabolism, the microbiome (which can both produce and consume NAD+ precursors), and epigenetic aging clocks represents fertile ground for future investigation.
As the field matures, important methodological considerations have come to the fore. Standardization of NAD+ measurement techniques, careful attention to tissue collection and processing protocols that prevent artifactual NAD+ degradation, and rigorous statistical design in preclinical studies are increasingly recognized as essential for generating reliable, cross-comparable data. The NAD+ research community continues to build a comprehensive molecular understanding of this ancient and essential coenzyme, with ongoing investigations expected to further illuminate the complex web of metabolic, signaling, and genomic maintenance functions that depend on adequate NAD+ availability.